Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05459844
What this trial is testing

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Who this might be right for
Neuroendocrine Tumors
Sinotau Pharmaceutical Group 196
Large-scale testing (Phase 3)Study completedNCT04852679
What this trial is testing

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 43
Not applicableStudy completedNCT01747096
What this trial is testing

TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Patients With Gastroenteropancreatic Neuroendocrine Tumors
Nantes University Hospital 130
Early research (Phase 1)Active Not RecruitingNCT04750954
What this trial is testing

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Neoplasm
National Cancer Institute (NCI) 29
Not applicableStudy completedNCT02730104
What this trial is testing

Community-based Neuroendocrine Tumor (NET) Research Study

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 100
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Ended earlyNCT02078843
What this trial is testing

Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Insel Gruppe AG, University Hospital Bern 54
Large-scale testing (Phase 3)Looking for participantsNCT05884255
What this trial is testing

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Who this might be right for
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 220
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Not applicableStudy completedNCT04986085
What this trial is testing

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 399
Early research (Phase 1)Looking for participantsNCT07080242
What this trial is testing

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Who this might be right for
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic Neuroendocrine Prostate Cancer+8 more
SystImmune Inc. 120
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Not Yet RecruitingNCT07842172
What this trial is testing

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

Who this might be right for
Neuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Neoplasm
Washington University School of Medicine 240
Early research (Phase 1)Looking for participantsNCT07165132
What this trial is testing

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+6 more
RayzeBio, Inc. 104
Not applicableActive Not RecruitingNCT04804371
What this trial is testing

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Health Network, Toronto 40
Not applicableActive Not RecruitingNCT03691064
What this trial is testing

Post-Authorization Long-Term Safety Study of LUTATHERA

Who this might be right for
Neuroendocrine Tumors
Advanced Accelerator Applications 1,014
Testing effectiveness (Phase 2)Ended earlyNCT02709889
What this trial is testing

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Who this might be right for
Malignant MelanomaMedullary Thyroid CancerGlioblastoma+5 more
AbbVie 200
Testing effectiveness (Phase 2)Looking for participantsNCT04837885
What this trial is testing

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

Who this might be right for
Neuroendocrine TumorLiver MetastasesNeuroendocrine Gastroenteropancreatic Tumour
University Hospital, Bordeaux 23
Not applicableStudy completedNCT04727723
What this trial is testing

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 164
Post-approval studies (Phase 4)Study completedNCT04524442
What this trial is testing

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications 42
Next Page
116